Pinnacle Wealth Management Advisory Group LLC Acquires 90 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Pinnacle Wealth Management Advisory Group LLC lifted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,569 shares of the medical equipment provider’s stock after buying an additional 90 shares during the period. Pinnacle Wealth Management Advisory Group LLC’s holdings in Intuitive Surgical were worth $529,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ISRG. Baystate Wealth Management LLC raised its position in Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the period. MCF Advisors LLC boosted its stake in Intuitive Surgical by 108.1% during the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 40 shares during the period. Atticus Wealth Management LLC raised its stake in shares of Intuitive Surgical by 85.4% in the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 41 shares during the period. MeadowBrook Investment Advisors LLC purchased a new position in shares of Intuitive Surgical during the 4th quarter worth about $30,000. Finally, OFI Invest Asset Management bought a new position in Intuitive Surgical during the 3rd quarter valued at about $25,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Myriam Curet sold 481 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $386.09, for a total transaction of $185,709.29. Following the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at $115,054.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now owns 1,842 shares of the company’s stock, valued at $736,800. The disclosure for this sale can be found here. In the last quarter, insiders sold 147,927 shares of company stock worth $57,064,459. Insiders own 0.80% of the company’s stock.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded down $8.28 during trading hours on Wednesday, reaching $380.37. The stock had a trading volume of 1,107,969 shares, compared to its average volume of 1,601,620. The company has a market cap of $134.92 billion, a price-to-earnings ratio of 68.66, a PEG ratio of 4.93 and a beta of 1.39. The business’s 50 day moving average price is $385.34 and its 200-day moving average price is $351.97. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the previous year, the business posted $1.00 EPS. Intuitive Surgical’s revenue was up 11.5% on a year-over-year basis. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Wells Fargo & Company boosted their target price on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research report on Friday, January 19th. Jefferies Financial Group lifted their target price on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Raymond James raised their price target on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Mizuho boosted their price objective on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Finally, BTIG Research raised their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.